Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Aaron R Mangold, M.D.
Mayo Clinic
Principal Investigator - Ali Moiin, MD
SciTech Development, Inc.
Study Director - Ann F Mohrbacher, MD
University of Southern California
Principal Investigator - Auris O Huen, MD, PharmD
M.D. Anderson Cancer Center
Principal Investigator - Barbara Pro, MD
Columbia University
Principal Investigator - Brad Haverkos, M.D.
University of Colorado, Denver
Principal Investigator - Christiane Querfeld, M.D., Ph.D.
City of Hope Medical Foundation
Principal Investigator - Dipenkumar Modi, MD
Barbara Ann Karmanos Cancer Institute
Principal Investigator - Jonathan Moreira, M.D.
Northwestern University, Robert H. Lurie Comprehensive Cancer Center
Study Director - Oleg E Akilov, MD, PhD
University of Pittsburgh Medical Center (UPMC)
Principal Investigator - Ryan A Wilcox, MD, PhD
University of Michigan
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Arizona
Scottsdale, Arizona, United States
Aaron R Mangold, M.D.Recruiting - City of Hope Medical Foundation
Duarte, California, United States
Christiane Querfeld, M.D., Ph.D.Recruiting - University of Southern California
Los Angeles, California, United States
Ann F Mohrbacher, M.D.Recruiting - University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Brad Haverkos, M.D.Recruiting - Northwestern University, Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States
Jonathan Moreira, M.D.Recruiting - University of Michigan
Ann Arbor, Michigan, United States
Ryan A Wilcox, MD, PhDRecruiting - Barbara Ann Karmanos Cancer Institute Wayne State University
Detroit, Michigan, United States
Dipenkumar Modi, M.D.Recruiting - Columbia University
New York, New York, United States
Barbara Pro, M.D.Recruiting - University of Pittsburgh Medical Center (upmc)
Pittsburgh, Pennsylvania, United States
Oleg E Akilov, M.D., Ph.D.Recruiting - the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Auris O Huen, MD, PharmDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 Dec 2023
- Primary completion
- 1 Dec 2026
- Completion
- 1 May 2027
- Last update posted
- 22 Sept 2025
- Registered enrollment
- 46
- Registry id
- NCT04234048
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.